文献速递前列腺癌

前列腺癌盆腔淋巴结清扫:局限性与扩大性清扫随机临床试验的更新结果

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
PubMed 文献 · Eur Urol · 2024-10-29

这项单中心随机试验于2011年10月至2017年3月入组1432例行根治性前列腺切除术的患者,比较局限性(髂外)与扩大性(髂外、闭孔及髂内)盆腔淋巴结清扫。中位随访4.2年时两组生化复发率相当(HR 1.05,95%CI 0.97-1.13;p=0.3);中位随访5.4年时扩大清扫对转移有保护作用(任何转移HR 0.82,95%CI 0.71-0.93;p=0.003)。

要点

  • 扩大盆腔淋巴结清扫未显著降低生化复发率(HR 1.05,95%CI 0.97-1.13;p=0.3)。
  • 扩大清扫对任何转移有保护作用(HR 0.82,95%CI 0.71-0.93;p=0.003)。
  • 扩大清扫对远处转移的保护作用为HR 0.75(95%CI 0.64-0.88;p<0.001)。

核心结论

  • 行根治性前列腺切除术的患者应接受扩大盆腔淋巴结清扫,包括髂外、闭孔及髂内淋巴结。
  • 进一步研究应探讨受累淋巴结解剖位置的生物学机制。
  • 其他癌症的淋巴结清扫试验是必要的,并应考虑本研究的临床整合设计。

研究设计与样本

  • 临床整合随机试验,于2011年10月至2017年3月在单中心入组1432例行根治性前列腺切除术的患者。
  • 外科医生按3个月交叉周期整群随机分配行局限性(髂外淋巴结)或扩大性盆腔淋巴结清扫(髂外、闭孔及髂内淋巴结)。
  • 采用按外科医生聚类的稳健标准误Cox比例风险回归评估清扫范围对生化复发或远处/区域转移的影响。

主要发现

  • 无生化复发参与者的中位随访为4.2年,共发生452例生化复发事件。
  • 两组生化复发率相当(HR 1.05,95%CI 0.97-1.13;p=0.3)。
  • 无转移患者的中位随访为5.4年,共发生123例转移事件。
  • 扩大清扫对任何转移有临床和统计学显著的保护作用(HR 0.82,95%CI 0.71-0.93;p=0.003)。
  • 扩大清扫对远处转移有保护作用(HR 0.75,95%CI 0.64-0.88;p<0.001)。

临床怎么用

  • 作者结论认为行根治性前列腺切除术的患者应接受扩大盆腔淋巴结清扫,包括髂外、闭孔及髂内淋巴结。

局限性

  • 研究在单中心进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Lymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated BCR rates and compare rates of metastasis between the study arms. METHODS: Between October 2011 and March 2017, 1432 patients undergoing radical prostatectomy were enrolled at a single center. Surgeons were cluster randomized to perform limited (external iliac nodes) or extended PLND (external iliac, obturator, and hypogastric nodes) with crossover for 3-mo periods. Cox proportional-hazards regression with robust standard errors clustered by surgeon was used to assess whether the PLND template affected BCR or distant or locoregional metastasis. KEY FINDINGS AND LIMITATIONS: There were 452 BCR events at median follow-up of 4.2 yr for participants who did not develop BCR. The results confirm our previous finding of comparable BCR rates between the arms (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.97-1.13; p = 0.3). However, with 123 metastasis events and median follow-up of 5.4 yr for patients without metastasis, we found a clinically and statistically significant protective effect of extended PLND against metastasis (any metastasis: HR 0.82, 95% CI 0.71-0.93; p = 0.003; distant metastasis: HR 0.75, 95% CI 0.64-0.88; p < 0.001). CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients undergoing radical prostatectomy should receive extended PLND that includes the external iliac, obturator, and hypogastric nodes. Further research should examine biological mechanisms regarding the anatomic location of affected nodes. Trials of LND for other cancers are warranted and should consider our clinically integrated design. This trial is registered on ClinicalTrials.gov as NCT01407263.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Touijer KA, Vertosick EA, Sjoberg DD, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. Eur Urol. 2024. PMID: 39472200. doi:10.1016/j.eururo.2024.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。